BlackRock Inc. lifted its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 6.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,393,015 shares of the company’s stock after acquiring an additional 309,138 shares during the quarter. BlackRock Inc. owned 11.10% of LivaNova worth $538,332,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of the stock. Wells Fargo & Company MN increased its stake in shares of LivaNova by 149.9% in the first quarter. Wells Fargo & Company MN now owns 895,623 shares of the company’s stock worth $79,263,000 after buying an additional 537,282 shares during the last quarter. State Board of Administration of Florida Retirement System increased its stake in shares of LivaNova by 18.9% in the first quarter. State Board of Administration of Florida Retirement System now owns 23,709 shares of the company’s stock worth $2,098,000 after buying an additional 3,770 shares during the last quarter. Swiss National Bank increased its stake in shares of LivaNova by 3.5% in the first quarter. Swiss National Bank now owns 71,419 shares of the company’s stock worth $6,321,000 after buying an additional 2,400 shares during the last quarter. Schwab Charles Investment Management Inc. increased its stake in shares of LivaNova by 8.1% in the first quarter. Schwab Charles Investment Management Inc. now owns 273,855 shares of the company’s stock worth $24,237,000 after buying an additional 20,419 shares during the last quarter. Finally, Aperio Group LLC increased its stake in shares of LivaNova by 69.2% in the first quarter. Aperio Group LLC now owns 11,523 shares of the company’s stock worth $1,020,000 after buying an additional 4,713 shares during the last quarter. 86.92% of the stock is owned by institutional investors.
LIVN has been the subject of a number of research analyst reports. Stifel Nicolaus lifted their price target on shares of LivaNova from $115.00 to $130.00 and gave the stock a “buy” rating in a research note on Tuesday, July 24th. Needham & Company LLC reiterated a “buy” rating and set a $106.00 target price (up previously from $102.00) on shares of LivaNova in a research note on Thursday, May 31st. BidaskClub upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Thursday, July 26th. Zacks Investment Research lowered shares of LivaNova from a “hold” rating to a “strong sell” rating in a research note on Thursday, May 17th. Finally, ValuEngine lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 17th. Three investment analysts have rated the stock with a hold rating, four have given a buy rating and two have issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $102.67.
LIVN stock opened at $123.75 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.51 and a quick ratio of 1.08. LivaNova PLC has a 1-year low of $62.67 and a 1-year high of $127.85. The firm has a market cap of $6.10 billion, a price-to-earnings ratio of 37.49, a price-to-earnings-growth ratio of 3.61 and a beta of 0.93.
LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, August 1st. The company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.04. LivaNova had a negative net margin of 4.93% and a positive return on equity of 9.24%. The firm had revenue of $287.50 million during the quarter, compared to analyst estimates of $278.08 million. During the same quarter in the previous year, the firm earned $0.93 earnings per share. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. equities research analysts predict that LivaNova PLC will post 3.24 earnings per share for the current fiscal year.
In other news, insider David S. Wise sold 1,500 shares of the company’s stock in a transaction dated Monday, July 16th. The shares were sold at an average price of $102.04, for a total transaction of $153,060.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the company’s stock in a transaction dated Wednesday, August 15th. The stock was sold at an average price of $121.58, for a total transaction of $121,580.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 8,058 shares of company stock valued at $888,223. 0.41% of the stock is owned by insiders.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Featured Article: Diversification
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.